title: Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
abstract: Multiple myeloma is a severe plasma dyschrasia with no known treatment or cure, even bone marrow transplantation. Cytokines such as tumor necrosis factor-alpha (TNF) and interleukin-6 (Il-6) are thought to be important trophic factors for the malignant plasma cells. In turn, histamine and nitric oxide are positive regulatory factors for Il-6. Here we note that the safe, approved and commonly used psychiatric medicines bupropion (Wellbutrin), paroxetine (Paxil) and quetiapine (Seroquel) are respectively potent TNF, nitric oxide and histamine antagonists and thus might find some use in treatment of multiple myeloma.
authors.affiliation: Department of Psychiatry, College of Medicine, University of Vermont, 2 Church Street, Burlington, VT 04501, USA.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kast
authors.forename: Eric Lewin
authors.initials: EL
authors.lastname: Altschuler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016642:Bupropion / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003987:Dibenzothiazepines / Q000008:administration & dosage*; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D017374:Paroxetine / Q000008:administration & dosage*; D000069348:Quetiapine Fumarate; D016896:Treatment Outcome
chemical_list: D003987:Dibenzothiazepines; D016642:Bupropion; D000069348:Quetiapine Fumarate; D017374:Paroxetine